A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.
As Immunomedics and Seattle both get backing from the big boys, antibody-drug conjugates finally come of age.
The upcoming virtual Esmo congress gives top billing to big pharma immunotherapies.
The UK big pharma is set to hand Japan’s Daiichi $1bn for rights to a second antibody-drug conjugate. Immunomedics watch out.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.